目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD
1.3.2 INCLUSIONS & EXCLUSIONS
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 ASSESSMENT OF MARKET SEGMENTS
2.4 ASSESSMENT OF GEOGRAPHIC SEGMENTS
2.5 MARKET BREAKDOWN & DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.7.1 METHODOLOGY-RELATED LIMITATIONS
2.7.2 SCOPE-RELATED LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 OPPORTUNITIES FOR PLAYERS IN BIOPSY DEVICES MARKET
4.2 NORTH AMERICA: BIOPSY DEVICES MARKET, BY END USER
4.3 BIOPSY DEVICES MARKET: GEOGRAPHIC SNAPSHOT
4.4 BIOPSY DEVICES MARKET: GEOGRAPHIC MIX
4.5 BIOPSY DEVICES MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2030 (USD MILLION)

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cancer
5.2.1.2 Increasing preference for minimally invasive surgeries
5.2.1.3 Initiatives undertaken by governments and global health organizations
5.2.1.4 Increased number of hospitals and diagnostic centers
5.2.1.5 Improved reimbursement policies
5.2.2 RESTRAINTS
5.2.2.1 Increasing product recalls
5.2.2.2 High risk of infections
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements
5.2.3.2 Growing investments in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Underdeveloped healthcare infrastructure in emerging economies
5.3 INDUSTRY TRENDS
5.3.1 MINIMALLY INVASIVE PROCEDURES
5.3.2 ROBOTIC-ASSISTED BIOPSY DEVICES
5.3.3 LIQUID BIOPSY TECHNOLOGY
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Robotic-assisted biopsy devices
5.4.1.2 Optical biopsy technologies
5.4.1.3 Minimally invasive biopsy devices
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Imaging technologies
5.4.2.2 Tissue analysis technologies
5.4.2.3 Artificial intelligence
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 Digital pathology and AI integration
5.4.3.2 Precision medicine tools
5.4.3.3 Advanced needle and probe technologies
5.5 PORTER'S FIVE FORCES ANALYSIS
5.5.1 THREAT FROM NEW ENTRANTS
5.5.2 BARGAINING POWER OF SUPPLIERS
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 THREAT FROM SUBSTITUTES
5.5.5 INTENSITY OF COMPETITIVE RIVALRY
5.6 REGULATORY LANDSCAPE
5.6.1 REGULATIONS, BY REGION
5.6.1.1 North America
5.6.1.1.1 US
5.6.1.1.2 Canada
5.6.1.2 Europe
5.6.1.3 Asia Pacific
5.6.1.4 Latin America
5.6.1.5 Middle East & Africa
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 PATENT ANALYSIS
5.7.1 PATENT PUBLICATION TRENDS IN BIOPSY DEVICES MARKET
5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.8 TRADE ANALYSIS
5.9 PRICING ANALYSIS
5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY KEY PRODUCT
5.9.2 AVERAGE SELLING PRICE TREND OF BIOPSY DEVICES, BY REGION
5.10 KEY CONFERENCES & EVENTS
5.11 KEY STAKEHOLDERS & BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 BUYING CRITERIA
5.12 BIOPSY DEVICES MARKET: UNMET NEEDS/EXPECTATIONS OF END USERS
5.13 ECOSYSTEM ANALYSIS
5.14 CASE STUDY ANALYSIS
5.14.1 CASE STUDY 1: DEVICELAB COLLABORATED WITH CLINICAL EXPERTS TO IDENTIFY LIMITATIONS OF EXISTING BREAST BIOPSY PROCEDURES
5.14.2 CASE STUDY 2: RESEARCHERS AT UNIVERSITY OF TWENTE DESIGNED ROBOTIC SETUP AND SOFTWARE ARCHITECTURE TO ASSIST RADIOLOGISTS IN TARGETING MRI-DETECTED SUSPICIOUS TUMORS
5.14.3 CASE STUDY 3: RESEARCH TEAM DESIGNED FLEXIBLE ROBOTIC SYSTEM FOR BIOPSY SAMPLING APPLIED TO HUMAN CORPSES PLACED INSIDE PROTECTIVE BODY BAGS
5.15 SUPPLY CHAIN ANALYSIS
5.16 ADJACENT MARKET ANALYSIS
5.16.1 BREAST BIOPSY DEVICES MARKET
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.18 INVESTMENT & FUNDING SCENARIO
5.19 IMPACT OF AI ON BIOPSY DEVICES MARKET

6 BIOPSY DEVICES MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 NEEDLE-BASED BIOPSY INSTRUMENT
6.2.1 CORE NEEDLE BIOPSY
6.2.1.1 Core needle biopsy device
6.2.1.1.1 Semi-automatic
6.2.1.1.1.1 Need for balance of user control and automated functionality in procedures to drive market
6.2.1.1.2 Automatic
6.2.1.1.2.1 Demand for efficiency and accuracy in biopsy procedures to boost growth
6.2.1.2 Core needle biopsy needle
6.2.1.2.1 Disposable
6.2.1.2.1.1 Need for infection control and safety concerns to boost growth
6.2.1.2.2 Reusable
6.2.1.2.2.1 Cost-effectiveness of reusable core biopsy needles to drive market
6.2.2 FINE NEEDLE ASPIRATION BIOPSY
6.2.2.1 Innovations in needle design, including thinner profiles and improved tip configurations, to drive market
6.2.3 VACUUM-ASSISTED BIOPSY
6.2.3.1 Increasing need for early and accurate cancer detection to drive market
6.3 VISUALIZATION DEVICE/SYSTEM
6.3.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC CONDITIONS TO DRIVE DEMAND FOR VISUALIZATION DEVICE
6.4 BRUSH BIOPSY INSTRUMENT
6.4.1 PREFERENCE FOR MINIMALLY INVASIVE BIOPSY PROCEDURES TO BOOST MARKET
6.5 BIOPSY ACCESSORY
6.5.1 BIOPSY FORECEP
6.5.1.1 General biopsy forcep
6.5.1.1.1 Demand for minimally invasive procedures and precise diagnostics to surge growth
6.5.1.2 Hot biopsy forecep
6.5.1.2.1 Unique ability of hot biopsy forecep to cut and coagulate tissue to support growth
6.5.2 TISSUE MARKER
6.5.2.1 Rising cases of breast cancer to boost market growth
6.5.3 LOCALIZATION WIRE
6.5.3.1 Ability of localization wire to detect precise target locations to drive growth
6.5.4 OTHER ACCESSORIES
6.6 ROBOTIC BIOPSY DEVICE
6.6.1 RAPID DEVELOPMENT OF ROBOTIC BIOPSY DEVICES TO BOOST GROWTH

7 BIOPSY DEVICES MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 ULTRASOUND-GUIDED BIOPSY
7.2.1 ULTRASOUND GUIDANCE ENHANCES SAFETY, MINIMIZES COMPLICATIONS, AND IMPROVES DIAGNOSTIC ACCURACY
7.3 STEREOTACTIC-GUIDED BIOPSY
7.3.1 NEED FOR EFFICIENT AND ACCURATE BIOPSY PROCEDURES TO SUPPORT MARKET GROWTH
7.4 OTHER TECHNOLOGIES

8 BIOPSY DEVICES MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 BREAST CANCER
8.2.1.1 Increasing demand for early and accurate diagnosis to boost growth
8.2.2 SOFT TISSUE CANCER
8.2.2.1 Advancements in diagnostics and growing emphasis on cancer therapeutics to drive market
8.3 GASTROENTEROLOGY
8.3.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE MARKET
8.4 BONE & BONE MARROW BIOPSY
8.4.1 RISING EMPHASIS ON BONE MARROW BIOPSIES TO SUPPORT MARKET GROWTH
8.5 OTHER APPLICATIONS

9 BIOPSY DEVICES MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & BREAST CARE CENTERS
9.2.1 DEMAND FOR STATE-OF-THE-ART BIOPSY FACILITIES TO DRIVE MARKET
9.3 DIAGNOSTIC IMAGING CENTERS
9.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
9.4 AMBULATORY SURGICAL CENTERS
9.4.1 GROWING FOCUS ON AMBULATORY CARE TO DRIVE MARKET
9.5 OTHER END USERS

10 BIOPSY DEVICES MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK
10.2.2 US
10.2.2.1 Growth in elderly population to drive market
10.2.3 CANADA
10.2.3.1 Rising government investments to drive growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK
10.3.2 GERMANY
10.3.2.1 Increasing prevalence of chronic diseases to propel market
10.3.3 UK
10.3.3.1 Initiatives by government to support market growth
10.3.4 FRANCE
10.3.4.1 Rising number of diagnostic imaging centers to drive market
10.3.5 ITALY
10.3.5.1 Availability of reimbursement coverage to support market growth
10.3.6 SPAIN
10.3.6.1 Increasing focus on cancer research to propel market
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK
10.4.2 CHINA
10.4.2.1 Rapidly growing geriatric population to propel market
10.4.3 JAPAN
10.4.3.1 High adoption of advanced technologies to support market growth
10.4.4 INDIA
10.4.4.1 Rising prevalence of chronic diseases to drive market
10.4.5 AUSTRALIA
10.4.5.1 Increasing investments in research to provide opportunities for market growth
10.4.6 SOUTH KOREA
10.4.6.1 Presence of well-developed healthcare systems to propel market
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK
10.5.2 BRAZIL
10.5.2.1 Favourable demographic conditions to drive market
10.5.3 MEXICO
10.5.3.1 Increased medical tourism and better government healthcare initiatives to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK
10.6.2 GCC COUNTRIES
10.6.2.1 Expansion of healthcare providers to drive growth
10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPSY DEVICES MARKET
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Product footprint
11.5.5.4 Technology footprint
11.5.5.5 Application footprint
11.5.5.6 End user footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 COMPANY VALUATION
11.7.2 FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES & APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS

12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 BD (BECTON, DICKINSON AND COMPANY)
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 Recent developments
12.1.1.3.1 Deals
12.1.1.4 MnM view
12.1.1.4.1 Key strengths
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 DEVICOR MEDICAL PRODUCTS, INC
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.3.1 Product launches & approvals
12.1.2.4 MnM view
12.1.2.4.1 Key strengths
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 MEDTRONIC
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 MnM view
12.1.3.3.1 Key strengths
12.1.3.3.2 Strategic choices
12.1.3.3.3 Weaknesses & competitive threats
12.1.4 CARDINAL HEALTH
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 MnM view
12.1.4.3.1 Key strengths
12.1.4.3.2 Strategic choices
12.1.4.3.3 Weaknesses & competitive threats
12.1.5 HOLOGIC, INC.
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.3.1 Deals
12.1.5.3.2 Other developments
12.1.5.4 MnM view
12.1.5.4.1 Key strengths
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 B. BRAUN SE
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 OLYMPUS CORPORATION
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.7.3.1 Deals
12.1.8 BOSTON SCIENTIFIC CORPORATION
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 FUJIFILM CORPORATION
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 STRYKER
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 TELEFLEX INCORPORATED
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 CONMED CORPORATION
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 MERIT MEDICAL SYSTEMS
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 JOHNSON & JOHNSON SERVICES, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 COOK GROUP
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.1.15.3.1 Product launches & approvals
12.2 OTHER PLAYERS
12.2.1 MICROPORT SCIENTIFIC CORPORATION
12.2.2 ARGON MEDICAL DEVICES
12.2.3 INRAD, INC.
12.2.4 SUMMIT MEDICAL LLC
12.2.5 TRANSMED7, LLC
12.2.6 DR. JAPAN CO., LTD.
12.2.7 IZI MEDICAL PRODUCTS
12.2.8 PLANMED OY
12.2.9 ADVIN HEALTH CARE
12.2.10 TRIVITRON HEALTHCARE

13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS